Viatris to Acquire Pacira BioSciences, Expanding Non-Opioid Pain Therapies
Viatris has agreed to acquire Pacira BioSciences, adding two marketed, patent-protected, high-margin medicines, EXPAREL® and ZILRETTA®, to its portfolio. The deal aims to strengthen Viatris' position in non-opioid pain management.
Pharmaceutical company Viatris has reached an agreement to acquire Pacira BioSciences. Financial terms of the transaction were not disclosed.
The acquisition will bring Viatris two U.S.-marketed, patent-protected, and high-margin non-opioid pain medications: EXPAREL® and ZILRETTA®. Viatris stated the move aligns with its strategy to advance innovative medicines and establishes the company as a significant player in the non-opioid pain therapy market.
Pacira BioSciences' products are primarily used for managing post-surgical pain. Viatris expects to leverage its existing global infrastructure to expand the international reach of these therapies into selected markets.
The transaction is anticipated to enhance Viatris' commercial, market access, and medical affairs capabilities for innovative medicines on a global scale, according to the company.